|
Summary
March 2008, Vol. 7, No. 2, Pages 147-158
, DOI 10.1517/14740338.7.2.147
Drug-induced crystal nephropathy: an updateSri G Yarlagadda1Yale University School of Medicine, Section of Nephrology/Department of Medicine, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA 2Associate Professor of Medicine Yale University School of Medicine, Section of Nephrology/Department of Medicine, LMP 2071, 333 Cedar Street, New Haven, CT 06520-8029, USA +1 203 785 4184; +1 203 785 7068; mark.perazella@yale.edu Background: Several medications that are insoluble in human urine are known to precipitate within the renal tubules. Intratubular precipitation of either exogenously administered medications or endogenous crystals (induced by certain drugs) can promote chronic and acute kidney injury, termed crystal nephropathy. Clinical settings that enhance the risk of drug or endogenous crystal precipitation within the kidney tubules include true or effective intravascular volume depletion, underlying kidney disease, and certain metabolic disturbances that promote changes in urinary pH favoring crystal precipitation. Objective: Identify and review previously described and recently recognized medications that cause crystal nephropathy. Method: A literature review was performed, using PubMed, Ovid, and Google Scholar, focusing on drugs (sulfadiazine, acyclovir, indinavir, triamterene, methotrexate (MTX), orlistat, oral sodium phosphate preparation, ciprofloxacin) that cause crystal nephropathy. Results/conclusion: Sulfadiazine, acylcovir, indinavir, triamterene, and MTX are known to cause crystal nephropathy. Recently, several medications, including orlistat, ciprofloxacin, and oral sodium phosphate solution, along with underlying risk factors have been described as causing crystal nephropathy. Forward Links to Citing ArticlesB. A. Vervaet, A. Verhulst, P. C. D'Haese, M. E. De Broe. (2009) Nephrocalcinosis: new insights into mechanisms and consequences. Nephrology Dialysis Transplantation 24:7, 2030-2035 Online publication date: 1-Aug-2009. CrossRef Kjeld Schmiegelow. (2009) Advances in individual prediction of methotrexate toxicity: a review. British Journal of Haematology Online publication date: 1-Jul-2009. CrossRef Christoph Boesecke, David A Cooper. (2008) Toxicity of HIV protease inhibitors: clinical considerations. Current Opinion in HIV and AIDS 3:6, 653-659 Online publication date: 1-Dec-2008. CrossRef Users who read this article also read:
|
|





Author for correspondence
TOC Alert